Finally, the increasing use of BRCA1/2 testing in somatic tissues for tailoring cancer treatment, in addition to classical germline testing for inherited predisposition diagnosis is switching the classical prevention scenario to mainstream oncology practice. This evidence concerns the gene BRCA1 and cancer.